文献速递头颈与中枢神经肿瘤

放疗后血浆EBV DNA联合TNM分期用于鼻咽癌辅助治疗风险分层

Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy.
PubMed 文献 · Ann Oncol · 2020-03-23

研究基于多中心前瞻性0502队列(n=745)开发并内部(n=340)和外部(n=837)验证风险模型,将放疗后EBV DNA水平与TNM分期结合,用递归 partitioning 分析分为低、中、高危组,5年OS分别为89.4%、78.5%、37.2%,模型区分度优于TNM分期或EBV DNA单独。

要点

  • 放疗后EBV DNA联合TNM分期可区分低、中、高危组,5年OS分别为89.4%、78.5%、37.2%。
  • 低危组5年OS与TNM II期相当(89.4% vs 88.5%),但可识别更多可免辅助治疗的患者(64.8% vs 28.1%)。
  • 模型区分度优于TNM分期或EBV DNA单独,并在内部和外部队列中验证。

核心结论

  • 放疗后EBV DNA联合TNM分期可改善鼻咽癌风险分层。

研究设计与样本

  • 模型开发基于前瞻性多中心0502 EBV DNA筛查队列(2006-2015年,n=745)。
  • 内部验证合并1997-2006年前瞻性临床研究独立队列(n=340)。
  • 外部验证使用中山大学肿瘤防治中心2009-2012年回顾性队列(n=837)。
  • 纳入UICC第7版II-IVB期、完成根治性放疗/放化疗、放疗后120天内检测EBV DNA且未接受辅助治疗的患者。
  • 主要终点为总生存,采用递归 partitioning 分析分为低、中、高危组。

主要发现

  • 联合放疗后EBV DNA水平(0、1-49、50-499、≥500 copies/ml)和TNM分期(II、III、IVAB),RPA模型将患者分为低、中、高危组,5年OS分别为89.4%、78.5%、37.2%。
  • RPA低危组5年OS与TNM II期相当(89.4% vs 88.5%),但识别更多可潜在免除辅助治疗毒性的患者(64.8% vs 28.1%)。
  • RPA模型c-index为0.712,优于TNM分期(0.604)或放疗后EBV DNA单独(0.675),校准度和一致性更好。
  • 结果在内部和外部队列中均得到验证。

临床怎么用

  • 整合放疗后血浆EBV DNA与TNM分期可用于鼻咽癌患者辅助治疗决策的风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: After curative radiotherapy (RT) or chemoradiation (CRT), there is no validated tool to accurately identify patients for adjuvant therapy in nasopharyngeal carcinoma (NPC). Post-RT circulating plasma Epstein-Barr virus (EBV) DNA can detect minimal residual disease and is associated with recurrence and survival independent of TNM (tumor-lymph node-metastasis) stage. We aimed to develop and validate a risk model for stratification of NPC patients after completion of RT/CRT to observation or adjuvant therapy. PATIENTS AND METHODS: The prospective multicenter 0502 EBV DNA screening cohort (Hong Kong NPC Study Group 0502 trial) enrolled from 2006 to 2015 (n = 745) was used for model development. For internal validation, we pooled independent patient cohorts from prospective clinical studies enrolled from 1997 to 2006 (n = 340). For external validation, we used retrospective cohort of NPC patients treated at Sun Yat-sen University Cancer Center from 2009 to 2012 (n = 837). Eligible patients had histologically confirmed NPC of Union for International Cancer Control (UICC) 7th Edition stage II-IVB who completed curative RT/CRT with or without neoadjuvant chemotherapy, had post-RT EBV DNA tested within 120 days after RT and received no adjuvant therapy. The primary end point was overall survival (OS). We used recursive-partitioning analysis (RPA) to classify patients into groups of low, intermediate, and high risk of death. RESULTS: Combining post-RT EBV DNA level (0, 1-49, 50-499, and ≥500 copies/ml) and TNM stage (II, III, IVAB), RPA model classified patients into low-, intermediate-, and high-risk groups with 5-year OS of 89.4%, 78.5% and 37.2%, respectively. The RPA low-risk group had comparable OS to TNM stage II (5-year OS 88.5%) but identified more patients (64.8% versus stage II 28.1%) that could potentially be spared adjuvant therapy toxicity. The RPA model (c-index 0.712) showed better risk discrimination than either the TNM stage (0.604) or post-RT EBV DNA alone (0.675) with improved calibration and consistence. These results were validated in both internal and external cohorts. CONCLUSION: Combining post-RT EBV DNA and TNM stage improved risk stratification in NPC.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Hui EP, Li WF, Ma BB, et al. Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy. Ann Oncol. 2020. PMID: 32217076. doi:10.1016/j.annonc.2020.03.289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。